SGLT2 inhibitor trial for children with kidney disease
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a medication called SGLT2 inhibitor (a type of diabetes drug that may also help protect the kidneys) in children with chronic kidney disease. It aims to see if the drug is safe and easy to use in children ages 2–18 with moderate to severe kidney problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has chronic kidney disease at stage 3 or 4 (moderate to severe kidney damage).
- Your child's estimated kidney function (eGFR) is between 20 and 60 mL/min/1.73m².
- Your child does not have heart disease, diabetes, or liver disease.
- Your child is not pregnant, does not have severe asthma, and is not on immunosuppressive medications.
- Your child has not had a solid organ transplant, chemotherapy, or stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called empagliflozin (usually used for diabetes) to see if it can help people with very advanced kidney disease and diabetes. The study will check if this drug can slow down further kidney damage and improve overall kidney health.
This study tests if an SGLT2 inhibitor can help protect kidney function in people who have lupus nephritis (kidney inflammation caused by lupus) and chronic kidney disease (CKD). The goal is to see if this medicine can slow down further kidney damage.
This trial tests if empagliflozin, a diabetes medicine that also protects the kidneys, can help people who have received a kidney transplant. It may be an option if you have reduced kidney function or diabetes after transplant.
This trial tests whether SGLT2 inhibitor drugs can protect kidney function in people with advanced chronic kidney disease who are not yet on dialysis. It may help slow further kidney decline.
This trial tests whether a type of medicine called SGLT2 inhibitors can help teenagers with early-stage chronic kidney disease. It looks at how safe and effective these drugs are for slowing down kidney damage.
This study looks at using a urine test to help diagnose and monitor chronic kidney disease (CKD), a condition where your kidneys slowly lose function over time. The study also checks how well a type of medicine called SGLT2 inhibitors (often used for diabetes) actually works in real life for people with CKD. If you have CKD, this research could help improve monitoring and treatment decisions.
Hear when a new Pediatric Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.